ClinicalTrials.gg

Program

gildeuretinol acetate

Also written as “ALK-001”, “ALK-001 oral capsule” and “ALK-001 (No generic name)”.

Its studies are mostly in Stargardt Disease · Geographic Atrophy, led by Alkeus Pharmaceuticals.

Furthest: phase 3, since Feb 15, 20195 company-led studies, 3 open or runningNext primary completion: Jun 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alkeus Pharmaceuticals53 open or runningphase 3since Feb 15, 2019Aug 27, 2014Jun 30, 2028phase 2 · NCT02402660

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 27, 2014First study: phase 1 study in Stargardt DiseaseFirst studyNCT02230228 · 40 enrolled
  2. Mar 9, 2015Phase 2 study in Stargardt DiseaseNCT02402660 · 160 enrolled · United States
  3. Feb 15, 2019Phase 3 study in Geographic AtrophyNCT03845582 · 200 enrolled · United States
  4. Jan 11, 2020Phase 2 study in Stargardt DiseaseNCT04239625 · 200 enrolled · United States
  5. Feb 10, 2026Phase 3 study in Stargardt DiseaseNCT07419334 · 230 planned · United States

Ahead

  1. Jun 30, 2028Primary completion: phase 2 study in Stargardt DiseaseNCT02402660
  2. Dec 2028Primary completion: phase 2 study in Stargardt DiseaseNCT04239625
  3. Oct 2029Primary completion: phase 3 study in Stargardt DiseaseNCT07419334

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07419334Stargardt Disease · United States3RecruitingOct 2029230
NCT04239625Stargardt Disease · United States2Active, not recruitingDec 2028200
NCT03845582Geographic Atrophy · United States3CompletedJul 25, 2023200
NCT02402660Stargardt Disease · United States2Active, not recruitingJun 30, 2028160
NCT02230228Stargardt Disease1CompletedSep 201440

How it is read

Names in the registry

  • “ALK-001”, 3 entries
  • “ALK-001 oral capsule”, 1 entry
  • “ALK-001 (No generic name)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.